Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Epacadostat · INCB-024360

Small molecule · Inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1) · developed by Incyte

Phase 3 Most advanced trial (none active)
2 Registered trials

What is Epacadostat?

Epacadostat is an orally available hydroxyamidine that inhibits indoleamine 2,3-dioxygenase 1 (IDO1), the enzyme that converts tryptophan into kynurenine. By reducing kynurenine, it is intended to restore immune cell proliferation and activation. It is studied in fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma and head and neck cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
INCB-024360
Drug type
Small molecule
Targets
Indoleamine 2,3-dioxygenase 1 (IDO1)
Mechanism
Inhibitor of Indoleamine 2,3-dioxygenase 1 (IDO1)
Pathways
tryptophan-kynurenine metabolism, dendritic cell, NK cell and T-lymphocyte activation, interferon production, regulatory T cell reduction
Therapy area
Oncology
Developer
Incyte Corporation
In trials of
CLDX, MRK
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
71596A9R13

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03358472 Phase 3 Head and Neck Cancer Completed MRK
NCT02166905 Phase 1/2 Fallopian Tube Carcinoma Completed CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Fallopian Tube CarcinomaHead and Neck CancerOvarian CarcinomaPrimary Peritoneal Carcinoma

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.